(AQST) – Globe Newswire
-
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
-
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
-
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
-
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA M
-
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
-
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
-
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting
-
Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference
-
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
-
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
-
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
-
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
-
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
-
Aquestive Therapeutics Completes $45 Million Debt Refinancing
-
Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET
-
Aquestive Therapeutics Provides Business Update
-
Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film
-
Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date
-
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
-
Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
-
Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
-
Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference
-
Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film
-
Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET
-
Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference
-
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit
-
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
-
Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findi
-
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
-
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
-
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
-
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
-
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
-
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
-
Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET
-
Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET
-
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
-
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
-
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
-
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
-
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
-
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
-
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
-
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
-
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI)
-
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI)
-
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
-
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
-
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
-
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
Back to AQST Stock Lookup